Abstract
In April 2009, the United States began a response to the emergence of a pandemic influenza virus strain: A(H1N1)pdm09. Vaccination began in October 2009. By using US surveillance data (April 12, 2009-April 10, 2010) and vaccine coverage estimates (October 3, 2009-April 18, 2010), we estimated that the A(H1N1)pdm09 virus vaccination program prevented 700,000-1,500,000 clinical cases, 4,000-10,000 hospitalizations, and 200-500 deaths. We found that the national health effects were greatly influenced by the timing of vaccine administration and the effectiveness of the vaccine. We estimated that recommendations for priority vaccination of targeted priority groups were not inferior to other vaccination prioritization strategies. These results emphasize the need for relevant surveillance data to facilitate a rapid evaluation of vaccine recommendations and effects.
Highlights
In April 2009, the United States began a response to the emergence of a pandemic influenza virus strain: A(H1N1) pdm09
We estimated the number of clinical cases, hospitalizations, and deaths prevented in the United States that were directly attributable to the 2009–2010 A(H1N1)pdm09 virus vaccination program
If we focus solely on children
Summary
In April 2009, the United States began a response to the emergence of a pandemic influenza virus strain: A(H1N1) pdm. By using US surveillance data (April 12, 2009–April 10, 2010) and vaccine coverage estimates (October 3, 2009–April 18, 2010), we estimated that the A(H1N1)pdm virus vaccination program prevented 700,000–1,500,000 clinical cases, 4,000– 10,000 hospitalizations, and 200–500 deaths. In July 2009, estimating that initial vaccine supplies could be insufficient to meet demand, the Advisory Committee on Immunization Practices (ACIP) recommended priority groups for the vaccination program. We estimated the number of clinical cases, hospitalizations, and deaths prevented in the United States that were directly attributable to the 2009–2010 A(H1N1)pdm virus vaccination program. These results can be used by public health officials, policy makers, and the public to evaluate this program and plan for the management of future pandemics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
